Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer.
We cultured lymph node lymphocytes (LNL) from lung cancer patients in the presence of recombinant interleukin 2 (rIL2). The ability of LNL to respond to rIL2 was not affected by the advance of cancer stage when tested for proliferation and for lymphokine-activated killer (LAK) activity. The LAK activity of LNL was comparable to that of the corresponding peripheral blood lymphocytes. The rIL2-induced proliferation of macrophage-depleted LNL was augmented by the reconstitution with autologous alveolar macrophages while the LAK activity was not affected. However, macrophage-reconstituted LNL expanded rapidly and reached higher cell densities and exhibited a significantly lower LAK activity than macrophage-depleted LNL. The diminished LAK activity in macrophage-reconstituted LNL were markedly augmented by the subculture at a low cell density. From these results, we conclude that LNL can be a good material for the postoperative LAK therapy and that macrophage is useful in culture of LAK cells.
Yano
T
T
Department of Immunology, Kyushu University, Fukuoka, Japan.
Yasumoto
K
K
Nomoto
K
K
D002450:Cell Communication; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology*; D008198:Lymph Nodes / Q000473:pathology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008938:Mitosis / Q000187:drug effects; D009367:Neoplasm Staging
D007376:Interleukin-2